Crizotinib (CAS 877399-52-5) is a high-purity anticancer API, a targeted tyrosine kinase inhibitor (TKI) designed to treat ALK/ROS1-positive non-small cell lung cancer (NSCLC). Its precise molecular structure enables specific binding to abnormal ALK/ROS1 kinases, blocking tumor cell proliferation and signaling pathways.
Produced under strict GMP standards, this API ensures high purity and consistent bioactivity, meeting global pharmaceutical quality requirements. It is primarily used in formulating oral anticancer medications, suitable for patients with locally advanced or metastatic ALK/ROS1-positive NSCLC, effectively delaying tumor progression and improving quality of life.
For pharmaceutical manufacturers and oncology research institutions, this anticancer API offers targeted efficacy, reliable quality, and compliance with pharmacopeia standards. It avoids non-specific cytotoxicity of traditional chemotherapy, supporting the development of safe, targeted anticancer drugs to address unmet needs in lung cancer treatment.
